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Abstract
Background:
Across Canada, waiting times for cardiac procedures, such as coronary artery bypass
grafting (CABO), are higher than the ideal waiting time. From 1994 to 2002, there was a
rapid increase in the number of patients receiving cardiac catheterizations and CABOs
across Canada. The rates in Newfoundland and Labrador (NL) were higher than the
Canadian average. This resulted in an extremely long waitlist with patients waiting
longer than the acceptable benchmark time to have their surgery. In 2004, the number of
people in Canada on cardiac surgery waitlists decreased significantly more than would be
expected from simple waitlist management. The main reason is that the number of
referral rates for CABO dropped dramatically. One major reason for this drop in referral
rates may have been due to the introduction of drug-eluting stents in Canada in 2003.
Objectives:
The objective of this study is to identify changes in referral patterns for coronary
revascularization and assess the impact on CABO waiting times in NL. This
retrospective study will identify the changes that occurred during this time period and
determine the reason(s) for these changes.
Method:
All 1341 patients who underwent a diagnostic cardiac catheterization in NL from Apri I I,
2005 to September 30, 2005 were included in this study. Records from the Cardiac
Program of Eastern Health were reviewed to determine referral rates, utilization rates, and
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wait times for percutaneous coronary intervention (pCl) and CABO procedures from
1998/1999 to 2007. The data obtained was compared to data from 1998/1999.
Results:
From 1998/1999 to 2005/2006 the number of coronary catheterizations increased by
21.6%. This was attributable to increased numbers of patients with stable angina,
myocardial infarction or chest pain of uncertain etiology, treated not by revascularization
procedures but by medical management. The proportion of patients diagnosed with
critical coronary artery disease (CAD) decreased by 5%. Patients with critical CAD were
referred for medical management, PCI, CABO or other. Referral rates increased 8.3% for
medical management, decreased 4.8% for PCI, decreased 5.1 % for CABO and increased
1.6% for other.
Between 2003 and 2007 the number of CABOs decreased by 12.7% and angioplasty
increased by 8%. Tn 2002, the year prior to introduction of drug-eluting stents (DES),
50% of those referred for revascularization were treated with PCI compared to 59% in
2007. Within one year of the introduction half of all stents comprised DES. Total stent
use has increased with an increase in DES and a decrease in bare metal stents (BMS). In
2005,63% ofstent cases received DES compared to 13.3% in 2003. Increased use of PCI
for unstable angina was observed in 2005 compared to 1998/1999 (73% v 61 %), but its
use in those with multi-vessel disease was similar in both years.
From 2002 to 2007, the number ofCABGs performed had an overall decrease from 568
to 492, and the waiting list went from 222 to 78. The recommended maximum waiting
time (RMWT) for CABGs are being reached for most patients in the semi-urgent « 2
weeks), short wait « 6 weeks), delayed wait « 6 weeks) and marked delay « 6 months)
priority groups. More than 80% of the patients in these groups are getting CABGs on
time. For very urgent « 24 hours) and urgent « 72 hours) patients, the percent reaching
the target for the RMWT is less than 50% but has increased since 1998/1999.
Conclusion:
The number of coronary catheterizations performed each year continues to grow,
however, the proportion diagnosed with critical CAD (69%) has decreased. CABG
numbers decreased at the time when DES utilization increased. Management of CAD in
the twenty-first century has changed rapidly. The rapid incorporation of DES in practice
has helped alleviate the problem of large CABG waitlists.
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Chapter 1 Introduction
1.1 Background
Management of coronary artery disease (CAD) has changed rapidly in the twenty-first
century. There has been a move away from coronary artery bypass graft (CABG) surgery
to less invasive procedures such as percutaneous coronary intervention (PCI) and
coronary artery stenting. Drug-eluting stents (DES) were introduced first in Europe in
2001, then in both Canada and the US in 2003 (1,2,3). DES have lower restenosis rates
than BMS (5% vs 12-20%, respectively) by incorporating a drug such as paclitaxel,
sirolimus, or everolimus that inhibit smooth muscle proliferation and prevent reocclusion
of the vessel (4, 5). When compared to CABG surgery, DES allow avoidance of general
anaesthesia, sternotomy and cardiopulmonary bypass. DES and CABG have similar one
year mortality rates, but BMS require more frequent revascularizations (6). The
introduction of DES has been associated with decreased use ofCABG (7, 8, 9,10).
In Europe, between 1994 and 2002, coronary catheterizations increased 3.2-fold, and PCI
increased six-fold with 85% of those patients receiving stents (1). Since 2001,26% of
patients who received stents had DES while the rest had bare-metal stents (BMS). In
Europe and the United States, the indication for PCI has shifted toward acute coronary
syndromes with increasing rates of interventions for acute MI and multivessel disease (1,
11). In the US, there has also been a rise in DES use and a decrease in CABG for
unprotected left main stenosis (12).
Utilization of CABO surgery and PCI with bare metal stent (BMS) insertion rose
dramatically across Canada from 1988 to 2002, including in Newfoundland and Labrador
(NL) (13,14,15). This led to increasing wait times for CABO and PCI both in Canada
andNL.
The increasing utilization of coronary catheterization, along with the increasing number
of people diagnosed with critical CAD, has exacerbated the problem of long waiting
times for cardiovascular services in Canada. In NL, several studies have confirmed the
need to increase funding for cardiovascular services. Prior to the introduction of DES in
2003, the number of CABO surgeries performed had an overall increase from 437 in
1998/1999 to 626 in 2001/2002. In 1998/1999, however, the proportion of patients who
had CABO within the recommended maximum wait time was not optimal (14, 16).
Optimal wait time was determined by a priority ranking that was calculated using the
pattern or severity of angina symptoms, the coronary artery anatomy and the results of
noninvasive tests of ischemic risk (17,18). The cases were categorized as follows: very
urgent (should undergo surgery within 24 hours), urgent (should undergo surgery within
72 hours), semi-urgent (should undergo surgery within 14 days during the same hospital
stay), short elective list (should undergo surgery within 6 weeks) and delayed elective list
(should undergo surgery within 6 months).
In 2004, the first Ministers increased funding for cardiovascular services in Canada (19,
20). This was a ten year plan created to strengthen health care delivery. One of the main
objectives was to provide better management of wait times and reduce wait times where
they were longer than medically acceptable. Five priority areas were identified including
cardiac care. A Wait Time Reduction Fund was established for $5.5-billion to augment
existing provincial and territorial investments and to assist jurisdictions in their own
particular initiatives to reduce wait times. The terms of this agreement were:
1) Each jurisdiction agreed to establish comparable indicators of access to health
care professionals, diagnostic and treatment procedures with a report to their
citizens to be developed by all jurisdictions by December 31, 2005.
2) Evidence-based benchmarks for medically acceptable wait times were to be
established by December 31, 2005.
3) Multi-year targets to achieve priority benchmarks were to be established by each
jurisdiction by December 31,2007.
4) Provinces and territories were required to report annually to their citizens on their
progress in meeting their multi-year wait time targets.
The Wait Time alliance was formed in 2004 to develop acceptable benchmarks and
makes several recommendations on ways to realize wait-time benchmarks and improve
patients' access to care. The NL benchmarks for CABO surgery were set at 2 weeks for
semi-urgent, 6 weeks for short wait and, 26 weeks for delayed wait patients (21).
Timeline:
1988-2002: CABG and PCI wait times increase
2001: DES introduced in Europe
2003: DES introduced in Canada and US
2004: First Minister's meeting to develop 10 year plan to reduce wait times
2005: NL benchmark set for CABG set according to the Wait Time Alliance
2005: Cohort of patients undergoing cardiac catheterization included in study
The current study was undertaken (a) to examine the utilization of cardiovascular services
for CAD following the introduction of DES in 2003, (b) to compare the clinical
characteristics of those who had coronary catheterization and critical CAD diagnosed in
2005 and 1998/1999, (c) to determine the clinical factors which influenced the
management strategy of critical CAD in 2005, (d) to compare the clinical characteristics
and wait times of those referred for CABG in 2005 to those in 1998/1999, and (e) to
assess the clinical characteristics of those who were treated with DES to those who
received bare metal stents in 2005.
We hypothesized that following the introduction of DES in NL in 2003 there would be
increased utilization of PCI that would be associated with decreased utilization ofCABG,
especially in those presenting with unstable angina and in those with multivessel disease.
We also hypothesized that CABG wait times would improve as a result.
1.2 Purpose
1. To identify all patients who underwent a diagnostic cardiac catheterization from
April 1,2005 to September 30,2005.
2. To determine the proportion of patients who underwent cardiac catheterization
and were diagnosed with critical CAD.
3. To determine if the proportion of those patients diagnosed with critical CAD by
cardiac catheterization has changed since 1998/99.
4. To identify treatment recommendations for patients with critical CAD.
5. To determine if treatment recommendations for patients with critical CAD have
changed since 1998/99.
6. To determine the clinical factors that influenced the management strategy of
critical CAD.
7. To determine if the introduction of DES has impacted referral practices for
coronary revascularization.
8. To determine urgency rating scores for patients referred for CABO.
9. To determine recommended and actual wait times for CABG.
1.3 Significance
This research will identify the changes that occurred during the time period from
1998/1999 to 2005 and determine the reason(s) for these changes, and whether the use of
DES was consistent with indications. The contributions it could make include future
planning of wait list management systems and allocation of resources.
Chapter 2 Review of Literature
2.1 Summary
A literature review was carried out using PubMed as the primary resource. MeSH
Database searches were used to find keywords. Articles were limited to English
language, human subjects and all adult categories. Section one of the literature review
will focus on the indications for each of the revascularization methods including CABO
and PCI as well as indications for medical management of critical CAD and whether one
method is preferred over another. In sections two and three, respectively, changes in
referral patterns for these treatments will be reviewed as well as the utilization of cardiac
services in NL and Canada. The focus of section four will be waiting times for PCI and
CABO both in NL and Canada. Finally, section five will examine how medical therapies
and drug-eluting stents have changed referral patterns for CABO.
2.2 Revascularization versus medical therapy for treatment of critical
coronary artery disease
Critical CAD is defmed as a reduction of 70% or greater in the luminal diameter of the
right coronary artery (RCA), the left anterior descending artery (LAD), the circumflex
artery and/or their major branches (17, 18). The definition also includes a reduction of
50% or greater in the luminal diameter of the left main coronary artery (LMCA). There
are three treatment options for patients who are diagnosed with critical coronary artery
disease (CAD) via cardiac catheterization. They are percutaneous coronary intervention
(PCI) with the use of a balloon or stent, coronary artery bypass grafting (CABO) surgery
and medical management. There are no clear indications for the use of anyone method,
as the best option for each individual patient is different. Clinical circumstances,
available revascularization options, and patient preferences need to be taken into
consideration. As technologies change, referral patterns for different treatment options
may change.
Revascularization procedures include CABG which is the most invasive method and
percutaneous coronary intervention (PCI) using a balloon or stents. CABG was preferred
over PCI in multi vessel and LMCA disease as well as in those with comorbid valvular
heart disease. CABG is normally the standard of care in patients with triple vessel or
LMCA disease, however, mortality rates and adverse outcomes such as death, myocardial
infarction or stroke are not different in the two groups (22, 23). PCl and CABG have
similar mortality rates but PCI has a higher restenosis rate requiring revascularization
with either repeat PCI or CABG (24). Elderly patients have more deaths in the first 6
months with CABG, as compared to PCI, but have better long-term survival (25). In
patients with previous CABG surgery, PCI is the preferred method ofrevascularization
(26).
Stenting can be done using either bare metal stents (BMS) or drug-eluting stents (DES).
Drug-eluting stents were introduced to try and relieve the problem of restenosis in
patients receiving stents. Sirolimus and paclitaxel are the two main drugs that coat the
DES to decrease restenosis. There was improvement in restenosis rates compared to
BMS but the rates are still higher in DES when compared to CABO. Studies comparing
DES to CABO have shown that mortality rates are the same but restenosis rates are
higher in the DES groups (27). Early studies of CABO versus DES showed that in the
short term (30 days), mortality was the same in both groups but the DES group had a
higher restenosis rate requiring repeat revascularization procedures (28). These results
have been reproduced for longer term studies (1-5 years) as well (29, 30, 31,32,33).
Results of studies comparing BMS to CABO show similar results (34). DESs are
associated with a greater number of stents placed, more areas stented and more
bifurcation stenting compared to BMS. Patients with high-risk unstable angina whose
age was greater than 70 years and had medically refractory ischemia, those with LV
dysfunction, and those with cardiogenic shock had no mortality difference when given
either CABO or PCI (35, 36, 37). For patients with unprotected LMCA disease treated
with either DES or CABG, no differences in cardiac or cerebrovascular events were
fOlmd (38). LMCA patients who received DES had lower rates ofMI and fewer repeat
revascularizations compared to those with BMS (39,40,41).
Studies have shown that DES have lower restenosis rates in the first year than BMS but
mortality was the same (42, 43, 44). After a three year follow up period, it has been
shown that the restenosis rates were no different in the DES and BMS groups (41). Other
studies have shown that patients treated with DES had lower rates of acute MI and death
(45,46). In patients who have had ST elevation MI (STEMI) there were no differences in
mortality or recurrent MI when comparing DES to BMS (47). Some early small studies
found that there was an increased risk of stent thrombosis with DES, however, in larger
randomized trials this was not shown to be a complication of DES compared with BMS
(48). In diabetic patients receiving PCI, significantly less in stent restenosis and fewer
major cardiac adverse events, including death, MI and stroke, were observed (49). In
patients with severe renal insufficiency (creatinine clearance <40 rnlJrnin) target lesion
revascularization was similar for DES and BMS (50).
Medical management of patients with CAD includes four standard medication classes:
anti platelet agents (aspirin, adenosine diphosphate receptor antagonists, or
dipyridamole.), beta-blockers, inhibitors of the renin-angiotensin system (angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker), and statins or other lipid-
lowering agents (51, 52). One large scale study revealed that having previous
revascularization procedures was associated with better use of these four guideline-
recommended medical treatments (53). A study comparing medical management with
PCI reported that in patients with chronic stable CAD, no significant differences between
the two treatment strategies were observed with regard to mortality, MI, or CABO or PCI
during follow-up (54). In patients with STEMI, the rates of repeat MI are higher with
medical management than with revascularization (55). Patients have better outcomes
with revascularization over medical management if they are male, non-smokers, and have
two or more risk factors (55). One study showed that optimal medical therapy
significantly reduces myocardial ischemia; however, PCI combined with medical therapy
produces an even greater reduction in ischemia (56).
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The three treatment modalities can be used interchangeably and the method used depends
on multiple factors including the clinical situation, patient preference and availability of
the treatments. There are no clear guidelines as to which method should be used and
research in this area is ongoing.
2.3 Changing referral patterns in NL and Canada
There have been numerous changes in the wait lists across Canada for many years.
Multiple factors have influenced the number of people on the wait lists including changes
in wait list management, actual waiting times for cardiac procedures and new
technologies developed for cardiac patients. CABG rates in Ontario increased by greater
than 30% between 1979 and 1983 and then remained stable through to 1988 (57).
Reasons cited for the large increase in CABG rates include an increasing elderly
population, increased use of diagnostic testing which would pick up critical CAD, and
increased use offacilities as elderly patients have longer stays in Intensive Care Units
(57, 58). With increased funding providing more efficient service and increased patient
capacity and the introduction of percutaneous transluminal coronary angioplasty (PTCA),
the wait list in Ontario decreased (57). Between 1988 and 1991, cardiac catheterizations
increased across the country by 8.5% but the wait time for this procedure did not change
(13). During that same time period, the rate ofPTCA increased by 38.5% and the rate of
CABGs increased by 20.6% (13).
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In 1991 a panel of cardiologists and cardiac surgeons in Canada derived principles for
ranking patients with critical CAD who require CABG (18). In Ontario, from 1991 to
1993, patients rarely suffered critical events such as death or MI while waiting for CABG
and did not have extreme delays in recieving CABG surgery (59). From 1994 to 2002,
there was a rapid increase in the volume of patients receiving cardiac catheterizations and
CABGs across Canada (14). Cardiac catheterizations increased 85% during that time
period and CABG increased approximately 20% (61). Rates ofCABG in Newfoundland
were consistently higher than the Canadian average. From 1997 to 2002, the age
standardized rate ofCABG in Canada ranged from 94.3 to 95.8 while NL ranged from
117.1 to 142.2 (62). This meant that the waitlist became extremely long and patients had
to wait longer than the acceptable benchmark time to bave their surgery (14). Many
patients were sent to the United States to have the procedure done within an acceptable
time period (63). Many reasons have been proposed for the long waiting times for CABG
in Canada including lack of buman resources, lack of infrastructure such as limited
equipment and limited operating time, poor system management, poor coordination of
services, and increased demand (19).
In 2004, the number of people in Canada on cardiac surgery waitlists decreased
significantly more than would be expected from simple waitlist management. This was
also observed in NL (64). There are a number of hypothesized explanations for this trend
including the introduction and increased use of DES, changing population demographics,
better medical therapies and a trend toward positive lifestyle changes. According to
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Sobolev et al, as waiting lists decrease, the waiting time should also decrease (65).
However, compared to 1993, the waiting time in 2004 was 92% longer (64).
2.4 Utilization of Cardiac Services in NL and Canada
In NL between April I, 1994 and March 31, 1995, 1604 patients had a coronary
catheterization done and of those, 1082 had critical CAD (16). Twenty-five percent of
those patients were referred for PCI, 36% were referred for CABO, and 33% were treated
with medical management. CABO was performed on 338 patients that year. Of these,
98.8% were considered appropriate and 93.8% were considered necessary. The numbers
of patients who underwent CABO in the recommended time were 24% of the urgent
patients, 64% of the semi-urgent patients, 50% of the short wait patients, and 75% of the
delayed wait patients. Most of the patients receiving CABO presented with late-stage
angina symptoms and advanced CAD. Based on these results, the government ofNL
increased funding to decrease wait times and the wait list size. However, the health care
delivery system was slow to provide the capacity to meet the demand.
Between 1994/1995 and 1998/1999 the number of coronary catheterizations increased by
37% and the number diagnosed with critical CAD increased from 64% to 74% (14). The
proportion of patients referred for PCI increased to 39%, medical management decreased
to 24% and CABO referrals stayed the same at 36%. More patients referred for CABO
were less acutely ill while PCI was used to treat the more acutely ill. CABO was deemed
necessary in 95% of patients. In 1994/1995,47% of patients received their CABO within
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the recommended wait time while this decreased to 39% in 1998/1999, with the delayed
wait patients having the largest decrease in the proportion of patients who received
surgery within the recommended wait time.
The number of revascularization procedures has not changed significantly from 2004 to
2007 in NL (60). In 2002/2003 the rate ofCABG was 42 per 100000 adults (62). In
2007/2008 the rate ofCABG was 105 per 100000 adults. In NL in 2007/2008, 58% of
coronary revascularization was done using PCI.
In Canada, the overall cardiac revascularization rate increased by 39% per 100 000
population from 1998/1999 to 2005/2006 (62). The rate went from 187 to 259 per
100 000 population. Since 2005/2006 the rate has started to decrease. Rates of CABG
went down by 2.8% and PCl increased by 66% from 1998/1999 to 2002/2003 (15). PCI
went from 96 per 100 000 in 1998/1999 to 177 per 100 000 in 2005/2006. The rate of
CABG decreased by 18% from 1998/1999 to 2007/2008 from 91 to 75 per 100000.
Across Canada in 2002 and 2003 the rate ofCABG was 71 per 100000 adult population
and the rate of PCI was 143 per 100000 adult population (19).
2.5 Wait time Benchmarks for CABG in NL and Canada
In September 2004, the First Ministers developed an agreement to increase funding across
Canada and to achieve acceptable wait times for cardiac procedures. Benchmarks for
CABG have been developed by the Wait Time Alliance and are presented in Table I (19).
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Table 1: Wait time benchmarks for CABG I
Urgency category
Emergency (unrelenting
cardiac compromise
unresponsive to all therapy
except surgery)
In house urgent (unable to
be discharged due to
need for intravenous
nitroglycerine, heparin, or
intra-aortic balloon pump
(lAB?))
Urgent outpatient
Non-urgent outpatient
Target
<90 minutes
1 day
7 days
6 weeks
Benchmark
<4 hours
7 days
14 days
6 weeks
IWait Time Alliance for Timely Access to Health Care. (2005). It's about time! Achieving benchmarks and
best practices in wait time management. Ottawa, ON: Canadian Medical Association.
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These benchmarks are guidelines only and do not take into account any constraints on the
capacity to meet these benchmarks. More realistic pan-Canadian benchmarks were set
by provincial and territorial governments. The NL government decided to set the
benchmark for CABO surgery at 26 weeks for delayed wait, 6 weeks for short wait and 2
weeks for semi-urgent patients. In Newfoundland, between July I and September 30 of
2006,97.8% ofCABG cases were completed in 182 days (26 weeks) (66). Information
regarding other priority groups was not available.
Studies have shown the outcomes of being on a waiting list for CABO negatively impact
patients including reduced employment and income, physical stress, lack of social
support, frustration, and decreased quality oflife (67, 68, 69, 70, 71, 72, 73). When
patients' surgeries are postponed they are more likely to feel anger and disappointment,
have additional tests conducted, procedures performed and medications prescribed, which
may lead to extended hospital stays and increased costs (74). Therefore it is not only
important for patients to have their procedures done within the benchmark for their health
and safety but also to minimize hospital and other healthcare costs. Risk factors that have
been shown to contribute to death while waiting for CABO are impaired left ventricular
function, advanced age, male sex and waiting longer than the recommended maximum
wait time (RMWT) (75).
2.6 Effect of drugs on referral patterns
There are three options for patients who are diagnosed with critical CAD: medical
therapy, which includes drug therapy and lifestyle modifications, percutaneous coronary
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intervention (PCl) and CABO. CABO is the most invasive therapy and there is a long
waiting list for the procedure. It may be possible that with the introduction of newer
drugs and more effective PCI, less CABOs need to be performed in order to achieve the
same effectiveness. Drug therapy should be given to all CAD patients and is generally
the primary option for patients with stable, low-risk CAD (76). The major classes of
drugs for patients with stable angina are nitrates, beta-blocker, and calcium channel
blockers while those with unstable angina also include intravenous heparin and
intravenous nitroglycerin (77). A study examining the impact of new cardiac
interventions, including drugs, PCI and CABO, over the past 30 years found that they all
decreased cardiovascular mortality (78). However, CABO led to a 44% reduction in total
mortality, STEMJ, or refractory angina requiring revascularization in patients with stable
multivessel CAD (79). While medical therapy can decrease mortality, CABO is clearly
better in stable patients. However, one European study reported that patients with stable
coronary artery disease who underwent revascularization procedures (CABO or PCI), had
more severe angina and an increased area of myocardium at risk (26).
Data on seniors who are on public drug programs in five provinces showed an increase in
the age and sex standardized rate of cholesterol lowering drugs by 79% between
2001/2002 and 2007/2008 (80). Statins have been shown to improve vein graft patency,
minimize recurrent ischemic events, and decrease the need for repeat revascularization
procedures in patients who have undergone CABO (8 I, 82). This could potentially
decrease the need for CABO procedures and therefore decrease the waiting list size and
waiting time.
17
2.7 Effects of drug-eluting stents on referral patterns
Drug-eluting stents are one of the treatments for critical CAD. They are placed in the
diseased artery and release a drug, either sirolimus or paclitaxel, which reduce the
incidence of restenosis of the artery. The use of drug-eluting stents allows avoidance of
general anesthesia, sternotomy, and cardiopulmonary bypass (83). They were first used
in NL in 2003. In-stent restenosis occurs in 12-20% of patients receiving bare-metal
stents (BMS) while it only occurs in approximately 5% of patients with DES (4). Patients
with multiple vessel disease treated with CABG and those receiving DES showed no
differences in mortality at one year, however, patients treated with CABG required fewer
revascularizations (6). Since it is a relatively new procedure, long-term outcomes are still
unknown. Because this procedure is less invasive and takes less time to perform, it is
predicted that physicians will refer more patients for DES than CABG. This would
decrease the amount of CABG surgeries performed. One study showed that the
introduction of DES decreased cardiac surgery volume by 21 % (7). The most common
predictors of a referral change from CABG to pcr with DES were diffuse coronary
narrowing, restenotic lesions, and small coronary arteries (7). Other studies have shown
modest decreases for CABG referrals after the introduction of DES (8, 9, 10). Long-term
outcomes of DES are required to determine whether long-term changes in referral
patterns for CABG will occur and whether patient outcomes are better with DES or
CABG.
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Chapter 3 Research Design
This is a retrospective study to determine whether physician referral patterns for coronary
revascularization have changed from 1998/1999 to 2005, and if they have, what was the
effect on nwnber of CABG surgeries performed. The study protocol was approved by the
Hwnan Investigation Committee at Memorial University ofNewfoundland, St. John's
and by the Research Proposal Approval Committee, a sub-committee of the Medical
Advisory Committee, Eastern Health, St. John's.
3.1 Utilization
All patients who underwent a diagnostic cardiac catheterization from April I, 2005 to
September 30, 2005 were included in this study. This data was obtained from the
manager of the cardiac catheterization laboratory at the Health Sciences Centre, St.
John's, NL. 1341 patients were identified as having had a cardiac catheterization during
this period. The records on cardiac catheterization, PCI, and CABG at the Cardiac
Program of Eastern Health were reviewed to determine the referral rates, utilization rates,
and wait list times for these procedures from 1998 to 2005. This program is the sole
provider of these services in NL, which had a population of 424, ISS aged IS years and
older in the 200 I census (84).
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3.2 Data Collection
From April I to September 30, 2005, an incident cohort of all patients having diagnostic
cardiac catheterization during that period was identified. Demographic, clinical and
diagnostic test data were collected as were records of the decisions made at the weekly
cardiovascular conference by cardiologists and cardiac surgeons regarding the type of
intervention to be applied to patients with critical CAD. Data was obtained from notes
from the cardiac catheterization procedure, the cardiovascular surgery conference and the
surgery itself, discharge summaries and letters of consultation, as well as results of
investigations such as stress tests and echocardiography. Data collected from patients
who had a cardiac catheterization included age, gender, indication for heart
catheterization, and whether the patient had critical CAD. Data from 1998/1999 was
obtained from previously published data (14).
3.3 Definitions
The definitions for unstable angina, angina class, asymptomatic CAD, significant CAD,
maximum medical therapy, results of noninvasive tests, coronary artery anatomy and
indications for cardiac catheterization or CABG were those approved by the RAND
Corporation Ratings of appropriateness and necessity by a Canadian panel (17, 18, 77,
85), and used in the previous studies (14, 16) in 1998/1999 and 1994/1995.
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Possible indications for heart catheterization were stable or unstable angina, MI, chest
pain of unknown origin, coronary heart failure (CHF), and other. For patients who had
non-critical CAD, no more data collection was required.
For patients who had critical CAD, data that was collected included coronary anatomy,
Left ventricular (LV) angiogram, ejection fraction (EF), comorbid diabetes mellitus types
I and II, Canadian Cardiovascular Society (CCS) angina class, very positive stress test,
maximal medical therapy, and recommendations for treatment. This data was obtained
using the computer-based Meditech system.
Coronary anatomy is based on the number of coronary arteries affected and their location.
Single vessel disease is critical CAD in at least one of the LAD, RCA, or circumflex
arteries. Double vessel disease is critical CAD in two of the LAD, RCA, or circumflex
arteries. PLAD involvement means there is critical CAD proximal to the fIrst septal
perforator. Triple vessel disease is critical CAD in all three of the LAD, RCA, and
circumflex arteries. Protected left main disease is critical left main CAD in the presence
of a patent bypass graft to the LAD or circumflex arteries, or by collateral flow to these
arteries from a patent RCA. Unprotected left main disease is critical left main CAD in
the absence of any patent grafts to the LAD or circumflex, or collateral flows to these
arteries from the RCA. Choices for coronary anatomy for data abstraction purposes were:
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1. Single vessel disease, no proximal LAD (PLAD) involvement:
2. Single vessel disease with PLAD involvement
3. Double vessel disease, no PLAD involvement
4. Double vessel disease with PLAD involvement
5. Triple vessel disease
6. Unprotected left main disease
7. Protected left main disease
A left ventricular angiogram measures the left ventricular ejection fraction (EF), which is
the fraction ofbJood pumped out of the ventricles with each heartbeat. It has been shown
that patients with a low EF «40%) have an increased mortality rate post CABG (86).
Ejection fraction data was used to detennine the grade of the ventricle.
I. Grade I ventricle - EF of greater than or equal to 50%.
2. Grade 2 ventricle - EF greater than or equal to 35% but less than 50%.
3. Grade 3 ventricle - EF of greater than or equal to 20% but less than 35%.
4. Grade 4 ventricle - EF of less than 20%.
CCS angina class has been in existence since 1976 and is used to determine the severity
of angina associated with activity. Table 2 lists the criteria for each angina class. Grade
IV angina is considered unstable.
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Table 2:
Grade
Gradel
Grade II
Grade III
Grade IV
Canadian Cardiovascular Society Angina Grading Scale (87)
Description
Ordinary physical activity does not cause angina, such as walking and
climbing stairs. Angina with strenuous or rapid or prolonged exertion at
work or recreation.
Slight limitation of ordinary activity. Walking or climbing stairs rapidly,
walking uphill, walking or stair climbing after meals, or in cold, or in
wind, or under emotional stress, or only during the few hours after
awakening. Walking more than two blocks on the level and climbing more
than one flight of ordinary stairs at a normal pace and in normal
conditions.
Marked limitation of ordinary physical activity. Walking one or two
blocks on the level and climbing one flight of stairs in normal conditions
and at normal pace.
Inability to carry on any physical activity without discomfort, anginal
syndrome may be present at rest.
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Stress testing is a non-invasive measure for diagnosis and risk stratification of myocardial
ischemia. It has a sensitivity of68% and specificity of 77% (88). A very positive stress
test has a positive predictive value of approximately 50% for left main or triple vessel
disease. A very positive stress test is defined as having one or more of the following
criteria (18):
• 2.5 mm ST depression
• ST elevation>1 mm in leads without q waves
• low workloads (heart rate <120)
• early onset ST segments in 1st stage (3 min)
• ST segment depression lasting longer than 8 minutes into recovery stage
• maximum heart rate> 120 on cardio-inhibitory medication
• SBP lowered at least by 10 mmHg
• ~ 3 beats of ventricular tachycardia
• new resting changes and/or reversible changes with pain
• high thallium: Suggest either anterior wall or multiple areas of myocardia to be in
ischemic jeopardy
• high halter monitor: For ambulatory ECG monitoring, shows prolonged and
unequivocal ischemia.
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Maximal medical therapy for stable angina includes patients who have received drugs
from at least two classes including beta-blockers, nitrates, and calcium channel blockers
or the patient is only on one of these drugs and is unable to tolerate the others (18).
Maximal medical therapy for unstable angina is defined as meeting one of the following
criteria (l8):
1) The patient must have received drugs from at least two classes including beta-
blockers, nitrates, calcium channel blockers, and intravenous (IV) heparin, or,
2) The patient must be receiving IV nitroglycerin, or
3) The patient must be receiving one class of drugs in (l) above and is unable to tolerate
the others.
Recommendations for treatment of critical CAD included medical management, PCI,
CABO, or other. For patients whose recommended treatment was either medical
management or other, no further data collection was required. For patients whose
recommended treatment was PCI, it was determined whether the patients had a coronary
stent inserted. If there was a stent insertion, then it was determined whether the stent
inserted was a BMS or a DES. For patients recommended for CABO, a more extensive
data collection was required. Clinical characteristics of patients diagnosed by cardiac
catheterization with critical CAD in 1998/1999 and clinical characteristics of patients
referred for CABO in 1998/1999 were compared to data from 2005.
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3.4 Priority scoring
Using a priority score developed by consensus, patients referred for CABO were ranked
according to need (14). The pattern or severity of angina symptoms, the coronary artery
anatomy and the results of noninvasive tests of ischemic risk determined the priority
ranking. Priority for CABO was calculated and waiting times for CABO were recorded.
Data from April I, 1998 to March, 1999 (12 months) were compared with those collected
in 2005 (6 months). The data from 1998/1999 came from a previous prospective study
with data collection occurring at the time of catheterization (14). This approach was not
feasible for this study due to limited resources.
The date accepted for CABO and the date of the CABO were used to calculate the
number of days awaiting CABO. An Urgency Rating Score (URS) was then calculated
for these patients. This was calculated using the Cardiac Care Network of Ontario URS
Calculator (89). This calculator includes data such as CCS angina class, vessel disease,
LV function, ischemic risk, co-morbidity, recent MI within 30 days of acceptance to
surgery, and previous CABO surgery.
From the URS, a RMWT was calculated. Patients were then categorized into priority
scales with RMWT as follows: Very urgent (patient should undergo surgery within 24
hours), urgent (should undergo surgery within 72 hours), semi-urgent (should undergo
surgery within 14 days during the same hospital stay), short wait (should undergo surgery
within 6 weeks), delayed wait (should undergo surgery within 3 months) and marked
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delay (should undergo surgery within 6 months). By comparing this categorization with
the length of time the patients actually waited for CABG, it was possible to make an
indirect assessment of the efficiency with which the cardiac surgery program delivers
CABG in NL. This data was compared to data from 1998/1999.
Coronary revascularization utilization data from 1998/1999 were compared to the data
from 2005. The number of cardiac catheterizations was obtained and the percentages of
those who were referred for CABG and PCI were calculated. The amount of CABGs
done and the number of people on the wait list was also obtained. The annual growth or
decrease in cardiac catheterizations, CABG surgeries and PCls was calculated and
compared from 2005 to 1998/1999.
All statistical analyses were carried out using Statistical Package for Social Sciences
(SPSS) version(s) 12.0 and higher. Descriptive statistics were u ed to describe the
samples and comparisons between groups were done using Student's t-test, Pearson chi-
square, Fisher exact, and multiple logistic regression as appropriate. The significance
level for all statistical tests was set at p < 0.05.
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Chapter 4 Results
4.1 Utilization of cardiovascular services for CAD
From 1998 to 2007, the number of cardiac catheterization procedures increased by 32%,
whereas the number referred for revascularization increased by 8%.
In the five years before the introduction of DES, the number of cardiac catheterization
procedures increased from 2196 in 1998/1999 to 2528 in 2002/2003, an increase of
15.1% (Table 3). Thjs coincided with an increase in the number ofCABGs performed
from 437 in 1998/1999 to 568 in 2002/2003, an increase 000%. In the five years
following the introduction of DES, the number of cardiac catheterization procedures
increased from 2844 in 2003 to 2903 in 2007, an increase of2.1 %. The number of
CABGs performed annually fell from 565 in 2003 to 492 in 2007, a decrease of 12.9%,
and the annual number of PC1 increased from 709 in 2003 to 766 in 2007, an increase of
8%.
In the year prior to the introduction of DES, 50% of those referred for revascularization
were treated with PCI, compared to 59% in 2007. The annual number of patients who
received DES increased from 89 in 2003 to 435 in 2007, an increase 0089% (Table 3).
Within one year of the introduction of DES, half of all stents inserted comprised DES.
There is overlap of the data in the year prior to (2002/2003) and the year following (2003)
the introduction of DES. Since tills study is examining 5-year trends and not changes
from year to year, this is not a significant limitation of the data.
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Table 3: Annual utilization of cardiovascular services in NL from 1998 to 2007
Prior to introduction of DES Following the introduction of DES
19981 19991 20001 20011 20021 2003 2004 2005 2006 20071999 2000 2001 2002 2003
Cardiac catheterization 2196 2269 2258 2389 2528 2844 2722 2801 2949 2903
Referred for CABO 578 613 628 717 654 677 665 552 588 543
Number of PCI performed 631 536 529 550 659 709 635 668 826 766
Number of DES used 89 311 419 509 435
% PCI receiving DES 13 50 63 64 60
Total revasc 1209 1149 1157 1267 1313 1386 1300 1220 1414 1309
% CABO of total revasc. 48 53 54 57 50 49 51 45 42 41
CABO performed 437 473 641 626 568 565 550 533 490 492
CABO wait list 227 308 223 243 222 218 260 271 88* 78
*Waitlistreassessed
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4.2 Clinical Characteristics
The clinical characteristics of patients who had a cardiac catheterization can be seen in
Table 4. Data seen in the tables may not always add up to the total number of patients
shown in the table as there was missing data in some categories. This will be addressed
in the limitations. The total number of diagnostic cardiac catheterizations that were
performed from April I, 2005 to September 30, 2005 was 1341. 65.5% of the patients
who had a cardiac catheterization were males. The mean age in years was 60.8 with a
standard deviation of 10.8. No published age or gender data was available for patients
who had cardiac catheterization in 1998/1999. Chi square test was used to compare
clinical characteristics of patients from 1998/1999 to 2005. Statistically significant
changes were noted for indications for cardiac catheterization. When comparing the
proportions of patients in each year it can be seen that unstable angina decreased by
17.2%, while MI/post MI angina, chest pain of uncertain origin and other indications
increased by 7.6%, 3.8% and 5.6%, respectively. Patients having an ejection fraction
< 35% had a small decrease of2.3%. The number of patients on maximal medical
therapy had a very significant drop from 70.9% to 28%. Out of the 1341 patient who had
cardiac catheterization in 2005, 46.7% had missing data for the maximal medical therapy
category due to limitations in data collection methods (Data not shown). Patients who
had a very positive stress test had a decrease of 4% from 1998/1999 to 2005. Significant
changes were seen in coronary anatomy from )998/1999 to 2005. There was an increase
in left main disease (2%), double vessel disease without PLAD (3.3%) and single vessel
disease without PLAD (4.3%). Decreases were seen in triple vessel disease (9.3%),
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Table 4: Clinical characteristics of patients who had cardiac catheterization in
1998/1999 and 2005
1998/1999 2005
12 months 6 months
(N=2071) (N=1341)
Mean (SO) Mean (SO)
Age, years 60.8 (±10.8)
N(%) N(%) X2 df p-value
Male 879 (65.5)
Indication for CC 147.0 4 0.000
Stable angina 673 (32.5) 434 (32.4)
Unstable angina 761 (36.7) 262 (19.5)
Ml/Post MI angina 372(18.0) 343 (25.6)
Chest pain of uncertain origin 96 (4.6) 113(8.4)
Other 169 (8.2) 185(13.8)
Ejection Fraction < 35% 256 (12.4) 127(9.5) 6.83 0.009
Maximal medical therapy 1468 (70.9) 376 (28.0) 601.60 I 0.000
Very positive stress test 366 (17.7) 177 (13.2) 12.17 0.000
Coronary Anatomy 78.0 0.000
Left Main 114(5.5) 101 (7.5)
Triple vessel 531 (25.6) 219 (16.3)
Double vessel with PLAD 161 (7.8) 58 (4.3)
Double vessel without PLAD 257 (12.4) 211 (15.7)
Single vessel with PLAD 150 (7.2) 55 (4.1)
Single vessel without PLAD 340 (16.4) 278 (20.7)
No critical CAD 516 (24.9) 410 (30.6) 13.18 0.000
CC - CardIac CatheterizatIOn
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double vessel disease with PLAD (3.5%) and single vessel disease with PLAD (3.1 %).
The number of patients without critical CAD increased by 5.7%.
The clinical characteristics of patients diagnosed by cardiac catheterization with critical
coronary artery disease are listed in Table 5. The number of patients who were diagnosed
with critical CAD after cardiac catheterization was 927 or 69%. Data was not available
for diabetes mellitus or maximal medical therapy in 1998/1999. Using Student's t-test to
compare means of age from 1998/1999 to 2005, it is shown that the means are
significantly different. When comparing the data from 2005 with that of 1998/1999, it
can be seen that the characteristics gender, very positive stress test and EF <35% do not
differ significantly. There is no data from 1998/1999 regarding the number of patients
with diabetes mellitus but 32% of patients in 2005 had diabetes at the time they were
diagnosed with critical CAD. A significant change in angina class was shown. Patients
with class I to II angina increased by 12.4% and those with class III angina decreased by
11.4%. The proportion of patients who did not have angina or whose angina status was
uncertain and those with class TV angina did not change much between 1998/1999 to
2005. No data is available for maximal medical therapy in 1998/1999 for comparison to
2005. Significant changes in coronary anatomy were seen. Left main disease increased
by 3.9%, triple vessel disease decreased by 11.4% and single vessel disease increased by
4.9%. Recommendations for treatment changed significantly from 1998/1999 to 2005.
CABO decreased by 5.4%, PCT decreased by 5%, medical management increased by 8%
and other management (i.e., heart transplant, implantable cardioverter-defibrillator)
increased by 1.6%.
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TableS: Clinical characteristics of patients diagnosed by cardiac
catheterization with critical coronary artery disease in 1998/1999 and
200S
1998/1999 200S
(N=162S) (N=927) t-test p-value
Mean (SD) Mean (SD)
Age, years 60(±11) 62 (±IO) -4.6838 0.000
N(%) N(%) X df p-value
Male 1152 (71) 674 (72.7) 0.96 0.327
Diabetes mellitus 297 (32.0)
Angina class 98.6 0.000
No angina/uncertain 117 (7) 57 (6.1)
Classlto II 131(8) 189 (20.4)
Class III 534(33) 200 (21.6)
Class IV 843 (52) 481 (51.9)
Very positive stress test 326 (20) 177(19.1) 0.35 0.554
Ejection fraction <35% 226 (14) 127 (13.7) 0.02 0.888
Maximal medical therapy 376 (40.6)
Coronary anatomy 39.1 0.000
Left main 119 (7) 101 (10.9)
Triple vessel 568 (35) 219 (23.6)
Double vessel 438 (27) 269 (29.1)
Single vessel 500 (31) 333 (35.9)
Recommendation for Treatment 30.3 0.000
CABG 578 (36) 284 (30.6)
PCI 631 (39) 315 (34.0)
Medical 397 (24) 297 (32.0)
Other 16 (1) 24 (2.6)
33
4.3 Clinical factors influencing management strategy of critical CAD
In 2005, 284 patients with critical CAD were referred for CABG. The clinical
characteristics of those patients are shown in Table 6. Characteristics that did not
significantly change from 1998/1999 to 2005 are age, gender, very positive stress test and
EF < 35%. Angina class changed significantly. Class !II angina decreased by 7.4%, class
IVa angina increased by 7.3% and class IVb or c angina decreased by 24.4%. The
number of patients diagnosed with critical CAD who were on maximal medical therapy
decreased significantly from 1998/1999 to 2005 by 35.5%. A significant change in the
coronary anatomy category was seen with increases in left main disease (8%), double
vessel disease without PLAD (5.7%) and single vessel disease without PLAD (4.3%).
There was a decrease in triple vessel disease of 15.3%. In 1998/1999 and 2005, the
majority of patients referred for surgery had either triple vessel disease or left main CAD
(69.7% in 2005 and 77% in 1998/1999), and a smaller proportion had single or double
vessel disease without PLAD (19% in 2005 and 9% in 1998/1999). This is consistent
with more severe disease being treated with CABG.
Two hundred and eighty four (30.6%) were referred for CABG and 315 (34%) for PCl in
6 months of2005 compared to 578 (36%) and 631 (39%) respectively in 12 months of
1998/1999 (Table 5). The clinical characteristics of patients diagnosed with critical CAD
by management strategy are presented in Table 7. CABG and PCl were combined to
form a revascularization strategy. In subgroup categories such as angina class and
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Table 6: Clinical characteristics of patients referred for CABG in 1998/1999
and 2005
1998/1999 2005
(N=578) (N=284) t-test p-value
Mean (SD) Mean (SD)
Age, years 62 (±9) 63 (±9) 1.533 0.126
N(%) N(%) X 2 df p-value
Male 445 (77) 227 (79.9) 0.96 1 0.327
Angina Class 50.3 0.000
No, IorII 67 (12) 44(15.5)
III 248 (43) 101 (35.6)
IVa 24 (4) 32 (11.3)
Nborc 239 (41) 47 (16.6)
Very positive stress test 154 (27) 75 (26.4) 0.01 0.920
Ejection fraction <35% 90 (16) 39 (13.7) 0.51 0.475
Maximal medical therapy 439 (76) 115 (40.5) 104.26 1 0.000
Coronary anatomy 36.9 0.000
Left Main 97 (17) 71 (25)
Triple vessel 348 (60) 127 (44.7)
Double vessel with PLAD 71 (12) 23 (8.1)
Double vessel without PLAD 39 (7) 36 (12.7)
Single vessel with PLAD 11 (2) 9 (3.2)
Single vessel without PLAD 12 (2) 18 (6.3)
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Table 7: Clinical characteristics of patients with critical coronary artery
disease by management strategy in 2005
Medical Revascularization
Management CABGIPCI
t-test
p-
N=297 N=599 value
Mean (SD) Mean (SD)
Age, years 63 (±11) 62 (±10) 1.3625 0.173
N (%) N(%) X2 df p-
value
Male 191 (64) 459 (77) 15.13 0.000
Age>75 37 (12) 60 (10) 1.23 0.267
Diabetic 90 (30) 200 (33) 0.86 0.353
Angina Class 31.7 0.000
None, I,ll 89 (30) 85 (14)
III 47 (16) 148 (25)
IV 138 (47) 290 (48)
Very positive stress
40 (14) 134 (22) 10.06 I 0.002
test
Ejection Fraction <
41 (14) 71 (12) 0.69 1 0.406
35%
Maximal medical
105 (35) 260 (43) 5.33 I 0.021
therapy
Coronary Anatomy 59.6 5 0.000
Left main 18 (6) 82 (14)
Triple vessel 48 (16) 163 (27)
Double vessel with II (4) 44(7)
PLAD
Double vessel
without 76 (26) 129 (22)
PLAD
Single vessel with II (4) 43 (7)
PLAD
Single vessel without
130 (44) 137 (23)
PLAD
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coronary anatomy, only proportions of patients from 1998/1999 to 2005 were compared.
No statistical analyses were performed for subgroups. Factors associated with a
revascularization management strategy rather than medical management included male
gender, angina class Ill, presence of a very positive stress test, on maximal medical
therapy and extent of CAD (left main, triple vessel, double vessel and single vessel with
PLAD). Factors associated with medical management rather than a revascularization
strategy included no angina or CCS angina class I to II and single vessel disease without
PLAD.
Table 8 shows the clinical characteristics of patients with critical coronary artery disease
by revascularization strategy in 2005. Factors associated with CABG rather than PCI
included diabetes, CCS angina class III, presence of a very positive stress test and extent
of CAD (left main and triple vessel disease). Factors associated with PCI rather than
CABG included higher CCS angina class (Class IV) and less severe CAD (double vessel
without PLAD and single vessel disease).
Multiple logistic regression was carried out using all the clinical variables collected.
Univariate comparison of factors is not provided in the thesis. Covariates were not
forced. The independent predictive factor identified by multiple logistic regression, for
revascularization rather than medical management was male gender (OR 1.75, CI 1.23-
2.51) (Table 9a). Angina class 0-2 (OR 0.38, CI 0.25-0.57) and single or 2 vessel di ease
(OR 0.41, CI 0.28-0.6.) were less likely to be associated with a revascularization strategy
rather than medical therapy. A very positive stress test (OR 1.57, CI 1.00-2.45)
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Table 8: Clinical cbaracteristics of patients witb critical coronary artery
disease by revascularization strategy in 2005
CABG PCI
N=284 N=315 t-test p-value
Mean (SD) Mean (SD)
Age,years 63 (±9) 61 (±II) 2.4196 0.016
N(%) N(%) X df p-value
Male 227 (78) 232 (74) 3.29 0.070
Age> 75 33(13) 27 (9) 1.54 0.215
Diabetic 108 (38) 92 (29) 5.23 0.022
Angina Class 70.6 0.000
None,I, II 44(15) 41 (13)
III 101 (45) 47 (14.9)
IV 79 (35) 211 (67)
Very positive stress test 75 (27) 59 (19) 5.07 0.024
Ejection Fraction < 35% 39 (14) 32 (10) 1.83 0.176
Maximal medical therapy 115(55) 145 (46) 1.87 0.171
Coronary Anatomy 206 0.000
Left main 71 (25) II (4)
Triple vessel 126 (45) 37 (12)
Double vessel with 23 (8) 21 (7)PLAD
Double vessel without 36 (13) 93 (30)PLAD
Single vessel with 9 (3) 34(11)PLAD
Single vessel without 18 (6) 119 (38)PLAD
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Table 9: Independent predictive factors for (A) coronary revascularization
rather than medical therapy and (B) for CABG rather than PCI in the treatment of
critical coronary artery disease
(A) Revascularization v medical mana~ement
Male
Angina class 0-2
Very positive stress test
Single or double vessel disease
Age> 75 years
Odds ratio*
1.75
0.38
1.57
0.41
0.59
9S0f0CI
1.23 - 2.51
0.25 - 0.57
1.00 - 2.45
0.28 - 0.60
0.34 - 1.01
*Multiple logistic model also included diabetes, class 3 angina, maximal medical therapy
and ejection fraction < 35% none of which approached statistical significance.
+ reference: unstable angina
An ina class 0-2+
Class3 an ina
1 or2 vessel disease
Multiple logistic model also included Age> 75 yrs, gender, diabetes, very positive stress
test, ejection fraction < 35% and maximal medical therapy none of which approach
statistical significance.
+ reference unstable angina
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and age >75 approached statistical significance (OR 0.59, CI 0.34-1.01) but because the
confidence interval included 1, it cannot be said that they are statistically significant.
Multiple logistic regression identified that the independent predictor for CABG rather
than PCI was stable angina (angina classes 0-3) while single and double vessel disease
were less likely associated with CABG rather than PCI (Table 9b).
4.4 CABG wait times by priority group
Urgency rating scores for CABG, calculated using definitions from Naylor, were used to
assign priority ratings and recommended waiting times to patients referred for CABG in
1998/1999 and 2005 (77). The results can be seen in Table 10. The results show that
there has been improvement in reaching recommended waiting times since 1998/1999.
All priority groups show an increase in the number of patients who have their CABG
within the recommended waiting time. Compared to 1998/1999, the percentage of
patients receiving their CABG within the recommended maximum wait time increased by
110% for very urgent patients, 50% for urgent patients, 90% for semi-urgent patients,
14% for short wait patients and 131% for delayed wait patients. In those classified as
urgent or very urgent, 45% had CABG within the recommended wait time in 2005
compared to 29% in 1998/1999, and in those classified as semi-urgent or short wait, 87%
had CABG within the recommended wait time in 2005 compared to 59% in 1998/1999.
There is no data from 1998/1999 regarding marked delay patients to compare to the 2005
data. The number of patients who had their CABG on time in the marked delay priority
group in 2005 was 78%, which is relatively high compared to the other priority groups.
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Table 10: Waiting times of patients referred for CABG in 1998/1999 and 2005 by priority and recommended
maximum waiting time
I 1998/1999 2005
(N=493) (N=284)
Recommended Total Target Target Total Target TargetPriority maximum I % Change
waiting time (N) (N) (%) (N) (N) (%)
Very
<24h 24 5 21 18 8 44 110Urgent
Urgent <72h 141 42 30 40 18 45 50
Semi-urgent <2 weeks 68 33 49 35 32 93 90
Short Wait <6 weeks 59 42 71 37 30 81 14
Delayed
<3 months 210 71 35 145 117 81 131
wait
Marked
<6 months 69 54 78Delay
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4.5 Coronary stent utilization
Drug-eluting stents were first used in NL in May 2003. Table 11 shows PCI and stent
utilization data since the introduction of DES from 200212003 to 200712008. During this
time period, the number of patient who had PCI and the number of patients who received
stents had slight increases of 8%. The total number of stents used was higher than the
number of patients receiving stents indicating that many patients received more than one
stent during their PCI procedure.
The number of BMS used declined by 51 % from 2003/2004 to 2007/2008. The year after
DES were introduced there was a drop in BMS use of 46%. The number of DES used has
risen by 518% since their introduction to 2007/2008. The number of patients receiving
DES has risen by 389% during this same time period. As with total stents, the number of
DES used is higher than the number of patients receiving stents. This indicates that many
patients are receiving multiple DES. The percent of stent cases receiving DES has risen
by 47%.
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Table 11: PCI and stent utilization data for 200212003 to 2007/2008
% Change
20021 20031 20041 20051 20061 20071 (2003/2004
2003 2004 2005 2006 2007 2008 to
200712008)
Total PCI 659 709 635 668 826 766 8
completed
# Patients
Receiving N/A 671 624 659 791 727 8
stents
Totalstents N/A 1068 901 1021 1260 1131 6
used
#BMSused N/A 962 516 463 514 476 -51
# DES used N/A 106 385 559 746 655 518
# Pts receiving N/A 89' 311 419 509 435 389DES
%ofstent
cases receiving N/A 13.3% 50% 63% 64% 60% 47
DES
*DES usage beginning May 2003
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Chapter 5 Discussion
5.1 Cardiac catheterization utilization
The data shows that between 1998/1999 to 2005 the number of cardiac catheterizations
increased by 28%. Similar results were seen in Alberta and British Columbia from 2000
to 2004 (93). That means that referrals for catheterizations must have also increased
during this period of time. The increased utilization of catheterizations in 2005 compared
to 1998/1999 was attri butable to a growth in the number of patients being investigated for
Ml/post MJ angina, chest pain of uncertain etiology and other various indications (i.e.
CHF). One possible reason for this increase in investigations is related to the aging
population ofNewfoundland. The average age of people receiving catheterizations in
2005 was 60.8±10.8 and the age group from 50 to 69 years old for the population of
Newfoundland has increased by 61.3% from 1996 to 2006 (94). Therefore more
catheterizations would be expected for this growing age group.
The proportion of patients who were diagnosed with critical CAD by cardiac
catheterization has decreased by 9% since 1998/1999. This is unexpected but may reflect
the increased number of patients being investigated for symptoms not necessarily caused
by CAD.
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5.2 Management strategies
The proportions of patients with critical CAD referred for different treatment options
including medical management, PCI, CABO or other, changed significantly from
1998/1999 to 2005. Medical management increased by 8%, PCI decreased by 5%,
CABO decreased by 5.4% and other increased by 1.6%. In 1998/1999 PCI was the most
common treatment option at 39% followed by CABO at 36% and medical management at
24%. In 2005, PCI was still the most common at 34% but medical management was
more common than CABO (32% vs. 30.6%). Therefore, it appears that the increased
numbers of patients diagnosed with critical CAD in 2005 were managed by medical
therapy rather than revascularization. This supports the previous statement that more
patients are being placed on medications to reduce the risk of cardiovascular events and
therefore fewer patients require more invasive procedures like CABO or PCI. Patients
with more severe CAD disease (left main, triple vessel, double vessel with PLAD and
single vessel with PLAD) were referred for revascularization rather than medical
management. Those patients were also more likely to have a very positive stress test and
be on maximal medical therapy. This is expected as a very positive stress test has been
correlated with more severe CAD and based on the CCS guidelines these patients should
be on maximal medical therapy (95, 96).
Referrals for CABO surgery were more likely if the patient had more severe disease or
was diabetic. Multiple studies have shown that CABO has better outcomes, including
less mortality and fewer major adverse cardiac events, in patients with multivessel and
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left main disease compared to PCI (97, 98, 99, 100, 101, 12, 103). Similar results were
seen in patients with diabetes (97, 99, 100, 101, 104). More patients with higher angina
class were referred for PCI than CABO, however, those referred for PCI had less severe
disease.
Since DESs were introduced in 2003, the total number of PCIs has increased as well as
the number ofpatients receiving stents. Total stent use has remained the same with an
increase in DES use and a decrease in BMS use. In 2007/2008, 60% of stent cases
received DES compared to 13.3% in 2003/2004. CABO numbers have decreased at the
time when DES utilization has increased.
5.3 Decreased CABG utilization
Coronary revascularization procedures for critical CAD are rapidly evolving. Rapid
incorporation of DES has occurred both in the USA (90) and in Canada (3) since their
approval. In NL, this rapid introduction has reduced the use of CABO and solved a major
health care delivery problem. Prior to the introduction of DES in 2003, there was a very
long waiting list causing long wait times for CABO. There was a need to increase the
number of CABOs that were performed. Introduction of DES has been associated with
partial substitution ofBMS with DES and an increased use of PCI, especially in those
with unstable angina. This occurred at a time when cardiac catheterization utilization
continued to increase and use of CABO in patients with stable angina continued to grow.
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Planning cardiac services in an era of rapid change is difficult but benchmarking the
provision of CABG is important (91). Previous recommendations for increased CABG
use in NL were based on the demonstration that referrals from cardiology were
appropriate, that a growth in necessary CABGs would continue, and that consistent
indications for CABG use would persist (14, 16). The predictions for the number of
CABGs have proven to be too high since the introduction of DES. Fortunately, the
introduction of DES occurred before resources, such as more operating rooms, surgeons,
perfusionists, anesthetists, and intensive care units, were provided to perform a higher
number of CABGs. However, there needs to be a constant evaluation of need and
utilization in order to provide an appropriate match between supply and demand of
cardiac services.
Current predictions of future DES utilization are based on the belief that DES relieve
obstructive coronary disease, provide durable mechanical results and do more good than
harm (90). However, there are some concerns as to whether DESs are safe in the long
term (2, 92). If these concerns prove to be true then DES utilization will decrease and
either BMS utilization may increase, CABG utilization may increase or a combination of
both may occur.
SA Wait Times for CABG
Wait times decreases have been reported for both CABG and PCI in other provinces in
Canada since the introduction of DES (93). Management of CAD in the twenty-first
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century has changed rapidly in that DESs are being substituted for the more invasive
CABO surgery. The rapid incorporation of DES in practice has alleviated the problem of
large CABO waitlists. Over five years, the number of CABOs performed decreased from
565 to 492, and the waiting list from 218 to 78. This is as expected as DES use increased
and the backlog of patients waiting for CABO was dealt with in the few years following
the introduction of DES in 2003.
The target RMWT for CABO is being reached for most patients in the semi-urgent (93%
in 2005 vs 49% in 1998/1999), short wait (81 % in 2005 vs 71 % in 1998/1999), and
delayed wait (81% in 2005 vs 35% in 1998/1999) priority groups. For very urgent (44%
in 2005 vs 21% in 1998/1999) and urgent (45% in 2005 vs 30% in 1998/1999) patients,
the target RMWT is still relatively low and, along with the short wait priority group, have
had only a moderate increase since 1998/1999. This shows that improvements are being
made but more work still needs to be done to increase access for the very urgent and
urgent priority groups. The very urgent and urgent groups have the sickest patients who
need CABO within a short period of time. These patients are the ones who should be
getting CABO within the recommended wait time but that target is still not being reached.
Some hypotheses as to why this is occurring are that there is not enough staff including
doctors and nurses to accommodate these people in such a short period of time. There
may also be problems in getting time in the operating room on short notice so patients
may be bumped until an operating room becomes available. Since these patients require
urgent CABOs they may become unstable and may have to wait before they have their
surgery until they have stabilized.
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As a result of the First Minister's Meeting in 2004, three budget programs were set up in
2007 to support patient wait times guarantees. In 2007, NL decided to focus on coronary
artery bypass grafting surgery in order to obtain funding through the Patient Wait Time
Guarantee Trust Fund ($612 million nationally, of which Newfoundland and Labrador
will receive $18 million) and be able to access funding through Canada Health Infoway
($400 million nationally) for the development of health information technology, such as
electronic health records and wait time information systems (21). As well, the Patient
Wait Times Guarantee Pilot Fund added an additional $30 million, which has been set
aside for provinces to undertake relevant, innovative pilot projects designed to help
implement their guarantees.
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Chapter 6 Summary
6.1 Conclusions
The purpose of this study was to determine how referral patterns for coronary
revascularization have changed and how this impacted waiting times for CABO. The
clinical characteristics of patients who underwent a diagnostic cardiac catheterization
from April 1,2005 to September 30,2005 were determined using data from various
sources including Meditech, chart reviews and the cardiac catheterization lab data. This
study showed that there has been an increase in cardiac catheterizations since 1998/1999.
This increase is attributable to a growth in the number of patients being investigated for
stable angina, MI, and chest pain of uncertain etiology. The proportion of patients who
had critical coronary artery disease was also determined by data from the above sources.
There has been a change in the proportion of patients diagnosed with critical CAD from
1998/1999 to 2005 from 78% to 69%, respectively. While more cardiac catheterizations
are being done, less critical CAD is being detected. This is in contrast to other centers in
Alberta and British Columbia where more catheterizations are being done but severity of
patient illness is increasing (93). Results from a US study also show an increase in
cardiac catheterizations during this time period, but again, report that there was an
increase in critical disease (105).
The referral patterns for those patients diagnosed with critical CAD has also changed.
The possible treatment recommendations include CABO, PCI, and medical management.
Referrals for CABO have decreased while there has been an increase in medical
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management. Even though referrals for PCI have remained the same, there has been an
increase in the number of PCls being performed and an increase in the number of people
receiving stents.
DES use has increased dramatically since its introduction in 2003 and this is directly
related to the decrease in CABG referrals. Introduction of DES has been associated with
partial substitution ofBMS with DES and an increased use of PCI, especially in those
with unstable angina. This change in management of critical CAD has significantly
decreased the size of the CABG waitlist in NL and therefore decreased the need for more
resources related to CABG utilization to be put in place in NL. DESs are a far less
invasive procedure than CABG and there are fewer risks associated with their use.
However, since DESs are a relatively new procedure more research needs to be done to
ensure their safety and efficacy over the long term. IfDESs are proven to be safe and
effective over the long term then a trend towards fewer referrals for CABG and more
referrals for PCI should continue. However, there needs to be constant evaluation of
supply and demand for CABG and DES utilization.
Urgency rating scores CURS) were calculated using the Cardiac Care Network of Ontario
URS Calculator (89). These scores were used to determine the patient's priority
grouping. The actual waiting times for the patient were observed and the recommended
maximum wait times (RMWT) were calculated. The RMWT for CABG is being reached
for most patients in the semi-urgent, short wait, delayed wait, and marked delay priority
groups. For very urgent and urgent patient priority groups, the RMWT is still relatively
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low and, along with the short wait priority group, has not changed significantly since
1998/1 999. More work still needs to be done to increase the very urgent and urgent
priority groups. More human resources, including doctors, nurses, and staff, and
increased operating room time could help increase the number of patients who reach the
target RMWT for these groups. Increased funding would be required to achieve this.
6.2 Limitations
There are several limitations to this study. One of the major limitations is the fact that the
data for this study was taken over a period of6 months in 2005 while the data to which it
is being compared came from a one year period. It is possible that the six months used in
this study is not representative of the entire year. Also, the one year period used is the
fiscal year 1998/1999. Since this overlaps calendar years, utilization data (Table 3) has
overlapping data in 2002/2003 and 2003. Due to different data collection methods for the
five years prior to and following DES introduction, they were unable to be separated to
determine actual change in utilization for those years. As this was a retrospective study,
there was no way to prove the accuracy of the data collection. As well there was no way
to recover missing data. Data was collected from three different sources, the cardiac
catheterization lab reports, Meditech, and hospital charts. Some required data could not
be found in any of the three sources while other data was contradictory. In cases where
there was a contradiction, data was abstracted in consultation with a cardiologist. The
accuracy of the data from each source was unknown. Data that was particularly hard to
obtain was maximal medical therapy as medications taken before the patient's cardiac
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catheterization were not always available. Therefore, much of this information was
missing and the results may not be accurate. Raw data for 1998/1999 was not available
so when the actual number was not available, a comparison to data from 2005 could not
be performed. A limitation in the statistical analysis of the study was the analysis of the
waiting times of patients referred for CABG. Some of the categories, especially the very
urgent, urgent, and semi-urgent priority groups had very small numbers of patients. This
may have skewed the data.
6.3 Future research and health policy implications
Future research needs to be done to determine whether the change in CABG wait times is
permanent due to ongoing changes in referral patterns. In future studies on wait times for
CABG surgery, data on vessel disease and other comorbidities such as valvular disease,
LV function, and renal disease needs to be captured as these can have an impact on which
management strategy is used (24, 33, 36, 50). Other data that has been shown to have an
impact on management strategy are previous revascularization, current medical therapies,
type ofM! and smoking status (55, 56, 79). DESs have become increasingly utilized over
CABG surgery since their introduction. However, the long term safety of DES needs to
be established. The type and number ofstents placed is important for future studies as
DES tend to be used in more complex disease as compared to BMS. Rates of restenosis
and in stent thrombosis, as well as other outcomes of critical CAD, including MI, stroke,
and death should be used to assess safety of DES versus CABG and medical
management. Both short term and long term data is required. Medical management for
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critical CAD is also increasing. Data regarding specific medications patients are taking
needs to be captured in the data analysis. These include anti platelet agents, beta-blockers,
inhibitors of the renin-angiotensin system and statins or other lipid-lowering agents. This
data can be used to determine whether the patient is on maximal medical therapy at their
time of diagnosis of critical CAD and how this impacts referrals and waiting times for
CABG. Further research is needed to determine why the wait times for very urgent,
urgent and short wait patient priority groups are still higher than the RMWT and how this
can be improved.
Wait list management is an important part of reducing wait times for CABG. Continual
monitoring of wait lists should be done to remove patients from the list if they die, move
away, decline the operation, accept surgery from another surgeon or switch to medical
management (106). Wait list management is a growing area of research and is needed to
determine the most efficient ways to maintain wait lists. Demand for CABG surgery
needs to be evaluated on a regular basis as technologies for management of
cardiovascular disease are changing rapidly. As well, new medical therapies are
developed rapidly and population lifestyles are changing. As demand for CABG change,
so does supply. Human resources, infrastructure such as equipment and operating time,
system management, and coordination of services need to be taken into consideration
when assessing supply. Continued funding of patient wait time guarantees by the
government and continual reassessment of supply and demand for CABG will help to
ensure optimal patient wait times in this era of rapid change in management of critical
CAD.
S4
Benchmarking the number of coronary revascularization procedures that should be
funded each year is important. As referrals for these procedures have been demonstrated
to be appropriate by a previous study, the number needed to be funded can be derived
from the number funded in the previous year (14). However, we have shown that new
intervention strategies may rapidly change the number of CABGs needed and therefore
the amount of funding will change. Consequently, benchmarking the number of
revascularization procedures that require funding should be reviewed annually.
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Appendix A
Chart Audit Form
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Chart Audit Form
Changes in Referral Patterns for Coronary Revascularization:
The Impact on Coronary Artery Bypass Grafting Surgery
Case Number:
Gender: I. Male 2. Female Age: __
Indication for Heart Catheterization: I. Stable Angina
2. Unstable Angina
3. Myocardiallnfarction
4. Post MI Angina
5. Chest Pain of uncertain origin
6.CHF
7.0ther,specify _
Date of Diagnostic Heart Catheterization: D_M_Y__
Critical Coronary Artery Disease (CAD): 1. Yes** 2. No
**If critical CAD is yes, continue with data collection
Coronary Anatomy: I. Single vessel disease, no proximal LAD (PLAD) involvement
2. Single vessel disease with PLAD involvement
3. Double vessel disease, no PLAD involvement
4. Double vessel disease with PLAD involvement
5. Triple vessel disease
6. Unprotected left main disease
7. Protected left main disease
LV Angiogram: I. Grade 1 ventricle
2. Grade 2 ventricle
3. Grade 3 ventricle
4. Grade 4 ventricle
Please give specific details of the lesion and the location of the lesion(s) (i.e. 80" mid RCA etc.)
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Ifthere is no data on the grade of the ventricle, please provide a general description of the
ventricle (i.e., generalized hypokinesis, or mild hypokinesis ofthe inferior wall etc)
Ejection Fraction < 35%: 1. Yes 2. No
Diabetes:
CCS Angina Class:
1. Yes
1. Class 1 t02
2. Class 3
3. Class 4
2. No
Very Positive Stress Test: 1. Yes 2. No
Maximal Medical Therapy 1. Yes 2. No
Recommendations for Treatment: I. Medical Management
2.PCI
3.CABG
4. Other, specify _
If the patient was referred for CABG complete the following:
Date accepted for CABG: D__M__Y_
DateofCABG: D_M__Y_
Number of days awaiting CABG: _
In order to calculate the Urgency Rating Score (URS) for CABG
complete the following, as per URS Calculator instructions:
A. Canadian Cardiovascular Society Angina Class:
I. Class 1 or2
2. Class 3
3. Class4A
4. Class4B
5. Class4C
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B. Vessel Disease
1. Left Main;:: 50% stenosis 1. Yes 2. No
2. IfPLAD has> 70% stenosis and ifthere is
> 70% stenosis in at least one of the following:
distal LAD, Circumflex, RCA. 1. Yes 2.No
3. IfPLAD > 70% and no other artery> 70% I. Yes 2.No
4. IfPLAD does not have> 70% stenosis or is blank;
is there >70% stenosis in all three of distal LAD,
Circumflex, or RCA? I. Yes 2. No
c.
5. There is not> 70% stenosis in all three of the
above arteries (Distal RCA, Circ, RCA)
i.e. at least one vessel < 70%
Left Ventricular Function
I. EF ;:: 50% or unknown
2. EF ;:: 35% and < 50%
3. EF ;:: 20% and < 35%
4. EF<20%
EF obtained via: 1. ECHO 2. MUGA 3. Cath
Date obtained: D_M_Y_
1. Yes
1. Yes
1. Yes
I. Yes
1. Yes
2. No
2.No
2. No
2.No
2. No
D. Ischemic Risk
I. High if:
I. High 2. Low
2.5 mm ST depression
ST elevation> I rom in leads without q waves
Low work loads (heart rate < 120)
Early onset ST segments in 1st stage (3 min)
ST segment depression lasting longer than 8 minutes into recovery
stage
Maximum heart rate < 120 on cardio-inhibitory medication
SBO lowered at least by 10 mmHg
;:: 3 beats of ventricular tachycardia
New resting changes and/or reversible changes with pain
High thallium: Suggest either anterior wall or multiple areas of
myocardia to be in ischemic jeopardy
High halter monitor: For ambulatory ECG monitoring, shows
prolonged and unequivocal ischemia
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2. Low if:
• Minor or no convincing findings for ischemia on exercise, ECG,
Holter monitor, or radionucleotide scanning
E. Co-Morbidity
I. Dialysis
c=J ;: ~~~etes
4.CYA
5.COPD
6.CHF
F. Recent Myocardial Infarction
MI within 30 days of acceptance to surgery
G. Previous CABG Surgery
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2.No
1. Yes 2.No
1. Yes 2.No
To determine the patient's Urgency Rating Score, add the values in the boxes A
through G. Enter that number here: _
Recommended Maximum Wait Time (RMWT)
To determine the RMWT, take the URS value that was calculated above, and apply to the
appropriate section below.
IftheURSis...
>= 1.01 and <=2
>= 2.01 and <= 3
>= 3.01 and <= 4
>= 4.01 and <= 5
>= 5.01 and <= 6
>= 6.01 and <= 7
>7.01
RMWT:
Use the following equation to calculate RMWT
RMWT = rNRS - 1 * 11 + 0
RMWT = [(URS - 2 * 2] + 1
RMWT=r(URS-3 * 11]+3
RMWT= r(URS-4 * 281 + 14
RMWT = [(URS - 5 * 481 + 42
RMWT = [(URS - 6 * 90] + 90
RMWT= 180
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If the patient was referred for PCI, complete the following:
1. Coronary Stent 1. Yes 2. No
2. Drug-Eluting Stent I. Yes 2. No
3. Indication for Drug-Eluting Stent: _
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Abbreviations
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Abbreviations (in alphabetical order)
BMS - Bare metal stent
CABO - Coronary artery bypass grafting
CAD - Coronary artery disease
CC - Cardiac cathterization
CCS - Canadian Cardiovascular Society
CHF - Congestive heart failure
DES - Drug-eluting stent
EF - Ejection fraction
LAD - Left anterior descending artery
LMCA - Left main coronary artery
LV - Left ventricular
MI - Myocardial infarction
NL - Newfoundland and Labrador
PCI - Percutaneous coronary intervention
PLAD - proximal left anterior descending artery
PTCA - Percutaneous transluminal coronary angioplasty
RCA - Right coronary artery
RMWT - Recommended maximum wait time
STEMI - ST elevation myocardial infarction
URS - Urgency rating score
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